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      Abstract
p16INK4a, a CDK4/CDK6 binding protein is an established 
tumour suppressor implicated in cell cycle regulation. 
Functional attributes of this protein are, therefore, 
important in determining optimal growth and proliferation 
of the mammalian cells. Accordingly point mutations and/or 
deletions that undermine its function have been associated 
with a variety of tumours. One such mutation that deletes a 
7bp region near the carboxy terminal ankyrin domain has 
previously been identified by us to associate with 
esophageal squamous cell carcinoma. The study represents 
construction, cloning and expression of the said mutation for 
its functional evaluation.
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Introduction
Cancer is a class of diseases in which a group of cells display uncontrolled 
growth, invasion and sometimes metastasis. These three malignant properties of 
cancers differentiate them from benign tumors, which are self-limited, do not 
invade or metastasize. To start with, the cancer cells are contained inside the body 
tissue from which they have developed – for example, the ducts of the breast, the 
top layer of skin, or the lining of the bladder.  All body tissues have a sort of 
fence, keeping the cells of that tissue inside, called the 'basement membrane'. At 
this stage, the cancer is called 'carcinoma in situ'.  Once the cells have broken 
through the basement membrane, it is called an invasive cancer (2).
Worldwide, the most common types of cancer that kill men are (in order of 
frequency): lung, stomach, liver, colorectal and esophagus. And those in case of 
women are (in the order of frequency): breast, lung, stomach, colorectal and 
cervical. One fifth of all cancers worldwide are caused by a chronic infection, for 
example human papillomavirus (HPV) causes cervical cancer and hepatitis B 
virus (HBV) causes liver cancer (3).
The global burden of cancer continues to increase with cancer related deaths 
projected to increase from 7.9 million to 11.5 million by 2030. The estimated rise 
takes in to account expected slight declines in death rates for some cancers in high 
resource countries. The new cases of cancer in the same period are estimated to 
jump from 11.3 million in 2007 to 15.5 million in 2030 (4).
Knowledge about the causes of cancer, and interventions to prevent and manage 
the disease is extensive. Cancer can be reduced and controlled by implementing 
evidence-based strategies for cancer prevention, early detection of cancer and 
management of patients with cancer. A third of cancers could be cured if detected 
early and treated adequately. In addition, more than 30% of cancer could be 
prevented (Danaei et al 2005), mainly by not using tobacco, having a healthy diet, 
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maintaining a healthy weight, being physically active and preventing infections 
that may cause cancer (3).
There are more than 200 different types of cancer and over 60 different organs in 
the body where a cancer can develop. It can develop from almost any type of cell 
in the body.  So there is usually more than one type of cancer that can develop in 
any one part of the body.  Though, one type of cancer will be much more common 
in a particular organ. For example, cells lining lungs are called squamous cells and 
also there are gland cells (cells with secretory functions) called adenomatous cells 
in the lungs.  So there are two types of lung cancers: squamous cell cancer and 
adenocarcinoma of the lung (5). 
The broad categories of cancer include: carcinoma (cancer that arises from 
epithelial tissue), sarcoma (cancer that arises from connective or supportive 
tissue), leukemia (cancer that starts in blood-forming tissue), lymphoma and 
myeloma (cancers that begin in the cells of the immune system), central nervous 
system cancers (cancers that begin in the tissues of the brain and spinal cord (1).
The main types of cancer leading to overall cancer mortality each year are lung, 
stomach, colorectal, liver, breast, esophagus, cervical and prostrate (3). 
Esophageal cancer is a disease in which malignant (cancer) cells form in the 
epithelial tissue of the esophagus. Of the two types of esophageal cancer, 
esophageal squamous cell carcinoma (ESCC) predominates over adenocarcinoma, 
with the former being more common in developing countries like India (I & II). 
While as adenocarcinoma of the esophagus has shown sharp increase in its 
incidence rate in developed nations particularly US and Western Europe (Blot et 
al., 1999).
Development of human esophageal cancer is a multistep, progressive process as 
all other human carcinomas. An early indicator of this process is an increased 
proliferation of esophageal epithelial cells (Lehrbach et al., 2003). While as 
esophageal adenocarcinoma develops from Barrett’s esophagus, a condition in 
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which normal squamous epithelium is replaced by metaplastic columnar 
epithelium. BE is therefore considered to be a pre-malignant lesion for esophageal 
adenocarcinoma (Spechler et al., 1994).
Esophageal Squamous Cell Carcinoma (ESCC) is the most common type of 
esophageal cancer, accounting for 95% of all esophageal cancers worldwide 
(Vizcaino, A. P, 2002).The lining of the esophagus is the most common region for 
cancers of the esophagus to begin. Esophageal cancer usually originates in the 
inner layers of the lining of the esophagus and grows outward. Most of the length 
of the esophagus is lined with squamous cells, which, if degenerate into a 
malignant tumor, give rise to squamous Cell Carcinoma (SCC).
Nearly all cancers are caused by abnormalities in the genetic material of the 
transformed cells which ultimately result in deregulation of the cell cycle. The 
orderly progression of cells through the cell cycle is governed by genes encoding 
proteins, which include positive regulators, such as the cyclins and cyclin 
dependent kinases (CDKs) & negative regulators such as p15, p16, p18, p21 and 
p27. Disturbance of these genes could contribute to cancers by allowing excessive 
cell proliferation.
In case of ESCC, several genes have been found to be frequently mutated,
however, p16INK4a is perhaps one of the few ones to register a variable spectrum 
of mutations in different populations owing to unique geographical and 
environmental factors, a population is exposed to (Muzeau et al 1997). Regions of 
high incidence in Asia, characterized as the “Esophageal Cancer Belt”, also 
exhibit striking variations within, presumably due to local dietary and 
environmental factors (Rosenberg et al 1985; Khuroo et al 1992) Kashmir borders 
this Esophageal Cancer Belt on the southern region. 
Kashmir valley has been reported as a high-incidence area of ESCC (Khuroo et al 
1992; Matoo 1974). ESCC accounts for 42.9% of all types of cancers in this 
region Dhar et al 1993). Kashmiri population distinguishes itself with unique 
geographical locale, intra community marriages, traditional dietary habits and 
unique cooking recipes in addition to potential exposure to nitroso compounds, 
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amines and nitrates present in the local food stuffs, such as dried and smoked fish, 
red meat, dried pickled vegetables and traditional hot salted green tea (Nun Chai) 
(Siddiqi et al 1988, 1989, 1991, 1992; Kumar et al 1990). The effects associated 
with unique diet are largely attributed to the presence of carcinogens or mutagens, 
which tend to aggravate the potential susceptibility of the population to the 
disease.
Like other carcinomas, cancers of the upper gastrointestinal tract are characterized 
by a deregulation of the normal cell cycle with alteration of the G1/S checkpoint 
(Rb pathway), including its regulators p16INK4a and cyclin D1 (Lin and Beerm 
2004). 
p16INK4a also known as CDKN2A, INK4A or MTS1, is an important component of 
cell cycle regulatory system.  It forms binary complexes with the cyclin dependent
kinases Cdk4 and Cdk6, inhibiting their ability to phosphorylate the RB protein 
(Serrano, M., 1993). Unphosphorylated RB prevents the cell from entering the cell 
cycle. Loss of p16 function, rendering the protein unable to bind & inhibit CDKs, 
can result in uncontrolled cell proliferation leading to tumorogenesis.  p16INK4a
gene deletions and other loss of function mutations, reported in a variety of 
tumors, substantiate its role as a tumor suppressor (Holland et al., 1994; Cairns et 
al., 1994; Caldas et al., 1994; Kamb et al., 1994b; Mori et al., 1994; Nobori et al., 
1994; Hussussian et al., 1994; Lukas et al., 1995; Koh et al., 1995; Ranade et al., 
1995). 
The alteration forms of p16 gene reported include deletion, mutation (Kamb, et 
al., 1994; Lang et al., 1998; Hashemi et al., 2000; Faderl et al., 2000; Cachia et al., 
2000; Mochizuki et al., 1999; Wang et al., 1999; Orlow et al., 1999; Kumar et al., 
1999), rearrangement, insertion (Srivenugopal et al., 1996; Nakamura et al., 
Orlow et al., 1999; Garcia-Sanz et al., 1997), translocation (Duro et al., 1996; 
Borg et al., 2000; Monzon et al., 1998) and hypermethylation of CpG islands 
presented in promoter sequence (Goussia  et al., 2000; Foster et al.,1998; 
Kempster et al., 2000; Zhang et al., 1999; Wong et al., 1997; Park et al., 2000; 
Salem et al., 2000). Recently, it has been reported that the exoteric p16 gene was 
transfected into the cancer cell lacking p16 gene, the cancer cell restored p16 gene 
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expression and cell growth was remarkably inhibited (Mobley et al., 1998; Allay 
et al., 2000; Steiner et al., 2000; Wolf et al., 1999; Wang et al., 1999; Lee et al., 
1999; Miyakoshi et al., 1997).
Apart from deletion of the whole p16INK4a locus, point mutations as well as small 
deletions resulting in the expression of truncated p161NK4a protein, could affect the 
function of this molecule. It, therefore, remains to be ascertained whether 
missense mutations, on the one hand, or non-sense, splice and deletion mutants 
leading to N- or C-terminal shortened p16INK4a proteins, on the other hand, have 
any impact on p16INK4a function. Transfection into the U20S cell line (Koh et al., 
1995) or microinjection into human diploid cells (Lukas et al, 1995) of p16INK4A
cancer-associated missense mutants showed that these mutations abrogated the 
inhibitory effect of this molecule on G1 progression.
There have also been several reports of mutations, which lead to truncated 
p16INK4a proteins. For example, the C to T transition in codon 85 leading to an 
Arg-to-Stop (Caldas et al., 1994; Kamb et al., 1994a), results in p16INK4a protein 
without the second half of the wild-type protein. Investigations have shown that 
mutations affecting the consensus amino acid residues compromise the structural 
integrity and functioning of p16INK4a protein.
All of the mis-sense mutations known to abrogate p161NK4a inhibitory activity 
(Koh et al., 1995; Lukas et al., 1995; Ranade et al., 1995) cluster in the second 
half of the molecule between amino acids 74 and 126. Some p16 mutants like 
G101, P114L and H123Q all have been found to be devoid of any CDK inhibitory 
activity (Byeon et al 1998). Studies have shown that the core region of p16INK4a
including the amino acids 73-131 as well as sequences N-terminal to amino acid 
73, are important for inhibition of cyclin DI/CDK4 kinase activity in vitro and that 
inhibition is strongly correlated with the ability to bind to CDK4. Binding assays 
reveal that inhibition was invariably associated with p16INK4a binding to CDK4 
since even minor perturbations in p161NK4a primary structure can lead to loss of its 
inhibitory activity possibly contributing to oncogenesis in numerous cell types. 
(Lilischkis et al 1996).     .  
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Our lab has recently identified a novel 7 bp deletion  in exon 2 of p16INK4a gene in 
a group of ESCC patients from Kashmir valley (Figure.1 & Figure.2).Several 
mutations in p16INK4a gene in other populations have been found to reduce its 
binding affinity with CDK. Studies have also revealed that inhibition is associated 
with p16INK4a binding to CDK4 (Lilischkis et al 1996). p16INK4a is an ankyrin 
repeat protein, containing four ankyrin repeats (I-IV), each having a helix-turn-
helix structure. The helices are designated as IA, IB, etc. The H-T-H motifs are 
connected by three loops designated as loop 1, loop 2 and loop 3. The ankyrin 
motifs mediate p16INK4a -CDK interactions. Mutations have been noted with 
highest frequency in three regions: residues 71-76, 80-102, and 107-127. The first 
segment lies in loop2; the second spans the entire ankyrin repeat III, and the third 
segment starts from loop3 and ends at the beginning of helix IVB (Byeon et al., 
1998). Ankyrin repeat domain in p16INK4a has come to be the focus due to the 
studies wherein it was established that the integrity of this region is important, 
both for structural as well as functional properties of p16INK4a protein (Zhang et al 
2000). The mutation, we have identified incidentally falls in this conserved part of 
the protein and could thus be highly significant with regard to function of p16INK4a
The said mutation occurring at the beginning of loop 3 that joins ankyrins III and 
IV of p16INK4a has the potential to dramatically distort the structural integrity of 
the protein. Thus a loss of p16INK4a function from the observed mutation is 
envisaged since tumor associated point mutations reported in this region viz, 
G101W, P114L and H123Q have all been found to be devoid of any CDK 
inhibitory activity (Byeon et al 1998).
A 7 bp deletion observed by us in Kashmiri population causes a frame shift in 
p16INK4a leading to deletion of a major portion of the carboxy terminus of 
p16INK4a. This mutation has the potential to seriously hamper the functioning of 
the protein. We have therefore chosen to investigate the effect of this mutation on
the interactive and regulatory role of p16INK4a in cell cycle, and this study 
constitutes a part of the objective.
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Review of Literature
2.1 DEFINING CANCER
Cancer is a complex family of diseases characterized by the cells that divide out 
of normal control and are able to invade other tissues through blood and lymph.
Interactions between the environment and a person’s individual genetic 
predisposition play an important role in the development of cancer. Carcinogens 
and environmental factors that have been implicated in causing cancer include 
viruses, chemicals and radiations. These factors directly or indirectly cause 
mutations within a cell which result in uncontrollable cell division and eventually 
a tumor. Cancer involves a pathological breakdown in the processes which control 
cell proliferation, differentiation and death of particular cells (II). In normal 
tissues, the rates of new cell growth and old cell death are kept in balance. In 
cancer, this balance is disrupted, which can result from uncontrolled cell growth 
or loss of a cell's ability to undergo cell suicide by a process called "apoptosis." 
Apoptosis, or "cell suicide," is the mechanism by which old or damaged cells self-
destruct (1)
   
    
Figure 2.1: Outlining how the loss of normal growth control leads to cancer. In 
normal tissues, the cell growth rate and old cell death rate are kept in balance, 
while as in cancer this balance is disrupted, causing uncontrolled cell division (1) 
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2.1.1 TYPES
Cancer types can be grouped into some broader categories. The main categories of 
cancer include (1): 
 Carcinoma - cancer that begins in the skin or in tissues that line or cover internal 
organs. 
 Sarcoma - cancer that begins in bone, cartilage, fat, muscle, blood vessels, or 
other connective or supportive tissue. 
 Leukemia - cancer that starts in blood-forming tissue such as the bone marrow 
and causes large numbers of abnormal blood cells to be produced and enter the 
blood. 
 Lymphoma and myeloma - cancers that begin in the cells of the immune system. 
 Central nervous system cancers - cancers that begin in the tissues of the brain 
and spinal cord 
2.1.2 EPIDEMIOLOGICAL DATA
In 2004, 7.4 million people died of cancer, around 13% of all deaths worldwide, 
with more than 70% of all cancer deaths occurring in low and middle income 
countries (3). The global burden of cancer continues to increase. The number of 
global cancer deaths is projected to increase 45% from 2007-2030 (from 7.9 
million to 11.5 million deaths, though influenced in part by an increasing and 
aging global population. The estimated rise takes in to account expected slight 
declines in death rates for some cancers in high resource countries. The new cases 
of cancer in the same period are estimated to jump from 11.3 million in 2007 to 
15.5 million in 2030 (4).
Cancer can be reduced and controlled by implementing evidence-based strategies 
for cancer prevention, early detection of cancer and management of patients with 
cancer. A third of cancers could be cured if detected early and treated adequately, 
based on the observation that treatment is more effective when cancer is detected 
earlier, i.e., when still localized. In addition, more than 30% of cancer could be 
prevented mainly by not using tobacco, having a healthy diet, maintaining a 
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healthy weight, being physically active and preventing infections that may cause 
cancer (Danaei et al 2005; 3).
2.2 CARCINOGENESIS
Cancer is a multistage process involving multiple genetic and epigenetic events in 
proto-oncogenes, tumor suppressor genes and anti-metastatic genes. During this 
process the cell develops defects in terminal differentiation, growth control, 
resistance to cytotoxity and programmed cell death. This evolution of the 
malignant cells is caused by the sequential accumulation of alteration in genes 
responsible for the control of cellular proliferation, cell death and the maintenance 
of genetic integrity (II). 
Figure 2.2: Flowchart illustrating how the sequential accumulation of alterations 
in genes controlling the cell cycle results in carcinogenesis and cancer 
development. (From NIH)
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A tumor is the outcome of an evolutionary process involving successive 
generations of cells, which progressively advance towards cancerous growth (III). 
Human histo pathological observations support this scenario and a range of 
premalignant lesions have been identified (IV). Tumor consists of cells whose 
growth and morphological characteristics are markedly different from those of 
normal cells. Criteria for malignancy include increased cell proliferation, loss of 
differentiation, infiltrative growth and metastasis to other organs (II).
                       2.3 GASTROINTESTINAL CANCERS
Gastrointestinal (GI) malignancies are a heterogeneous group of diseases that are 
categorized by organ of origin and histological type. GI malignancies are the most 
common type of human solid cancer worldwide. However the incidence varies 
dramatically from organ to organ within the GI system. Even within a single 
organ site in the GI system, the incidences can be highly variable because of 
different genetic and environmental factors. Gastrointestinal cancer includes 
cancer of the digestive system - the esophagus, colon, rectum, anus, liver, 
pancreas, and other digestive organs, while as some uncommon GI cancers 
include appendix, bile duct, gallbladder, and small intestine cancer (V).
2.4 ESOPHAGEAL CANCER
Esophageal cancer is a disease in which malignant cancer cells form in the tissues 
of the esophagus. The esophagus is the hollow muscular tube measuring 20-25 cm 
long and 2-3 cm wide, which moves food and liquid from the mouth to the 
stomach. The wall of the esophagus is made up of several layers of tissue, 
including mucous membrane, muscle and connective tissue. Esophageal cancer 
starts at the lining of the esophagus and spreads outwards through the other layers 
as it grows (7).
Cancer of the esophagus is among the most common and severe malignant 
neoplasms worldwide and occurs as two major histological types: squamous cell 
carcinoma (SCC) and adenocarcinoma (ADC). Squamous cell carcinoma is more 
evenly distributed throughout the length of the esophagus, adenocarcinoma is
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predominantly a disease of the distil esophagus and gastroesophageal junction, 
and is rarely found in the cervical esophagus (portion extending from the inferior 
aspect of the cricoid cartilage to the thoracic inlet) (8).
The esophagus itself has several unique properties that distinguish the behavior of 
cancer in this organ from that of other gastrointestinal malignancies. In contrast to 
the rest of the gastrointestinal tract, the esophagus has no serosa, thus reducing the 
resistance against local spread of invasive cancer cells. Furthermore the esophagus 
has an extensive network of lymphatics, allowing for early regional tumor
advancement (8). Majority of cancers in the upper two thirds of esophagus are 
squamous cell carcinoma in nature (9). Esophageal squamous cell carcinoma 
arises from stratified squamous non-keratinizing epithelium that lines the 
esophagus (10). 
Adenocarcinoma, which is most common in the mid and distal esophagus, arises 
from abnormal esophageal mucosa in a well-characterized sequence. In reaction to 
chronic gastroesophageal reflux, metaplasia of the normal stratified squamous 
epithelium of the distal esophagus occurs, resulting in a specialized intestinal 
glandular epithelium containing goblet cells, called Barrett epithelium (Spechler 
et al., 1994; Lagergren et al., 1999; Shalauta et al 2004; Pisegna et al., 2004; 
Wong et al., 2005). Further genetic alterations in this epithelium lead to dysplasia, 
which may progress from low-grade to high-grade dysplasia and, ultimately, to 
adenocarcinoma (8). Barrett’s esophagus is associated with a greater than 20-fold 
increased risk of esophageal adenocarcinoma (Spechler et al., 1984; Cameron et 
al., 1985; Hameeteman et al., 1989; Ovaska et al., 1989; Miros et al., 1991; 
Moghissi et al., 1993; Drewitz et al., 1997; Eckardt et al., 2001). The frequency of 
ADC is increasing in Western countries, and adenocarcinomas accounts for 
approximately 50% of all esophageal cancers in the United States (Blot et al., 
1991; 1993; 1999).
Esophageal cancer is considered one of the deadliest malignancies with increasing 
incidence rates world over. It is the sixth leading cause of cancer death worldwide 
(Parkin et al., 2005; Devassa et al., 1998). Overall, the five-year survival rate is 
between 15%-24%, the primary reason being detection at an advanced stage. By 
the time symptoms appear 2/3rd of the esophageal lumen is already obstructed by 
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the tumourous growth. Since esophagus has no serosa, as such, any tumour 
extension beyond the esophagus can spread rapidly (6).
Despite advances in surgical techniques and treatment, the prognosis of 
esophageal cancer remains poor, with very few long term survivors. The need for 
novel strategies for early detection of esophageal cancer to improve current 
therapy is therefore urgent (Ekman et al., 2007).
2.4.1 SIGNS AND SYMPTOMS
Esophageal adenocarcinoma and SCC have similar clinical manifestations, which 
usually reflect the extent of local esophageal involvement (8,10). The following 
are the symptoms associated with esophageal cancer:
 Dysphagia, the most common presenting symptom, i.e, difficulty in swallowing, 
usually develops in response to solid foods and progresses gradually to interfere 
with the intake of softer foods and, finally liquids (8). Dysphagia, which is present 
in approximately 70% of all patients at diagnosis (Enzinger et al., 2003) usually, 
occurs late in the course of the disease when two-third of the esophageal lumen 
has been narrowed (10).
 Pain is frequent and can occur in the absence of dysphagia. It can be related to 
swallowing itself (odynophagia), or to the local extension of the tumour into 
adjacent structures, such as pleura, mediastinum, or vertebral bodies (8).
 Regurgitation of food, heartburn, malaise (bodily discomfort), cachexia (general 
ill health and malnutrition (8). 
 Weight loss is noted in more than 70% of cases, and if present carries a worse 
prognosis. Weight loss is common and correlates with dysphagia, dietary changes, 
and tumour related anorexia. As eating becomes more difficult, calorie 
consumption is not enough to maintain the body weight. 
 Hoarseness, hiccups and sometimes vomiting of blood. These signs and 
symptoms usually don't appear until cancer is quite advanced. Hoarseness caused 
by invasion of the recurrent laryngeal nerve is a sign of unresectability, and 
hiccups from phrenic nerve involvement (8)
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2.4.2 DIAGNOSIS/DETECTION
2.4.2.1 CLINCAL DETAILS
         At the time of diagnosis, weight loss and dysphagia are the most common 
symptoms. Dysphagia usually appears when the esophageal lumen has been 
narrowed by 50-75%. Less commonly, presenting symptoms may be related to 
local invasion or metastases. Signs and symptoms include stridor, cough, and 
aspiration, pneumonia as the result of erosion into the tracheobronchial tree; 
hemoptysis (coughing up of blood or of blood-stained sputum from the bronchi, 
larynx, trachea, or lungs) or hematemesis (vomiting up blood) resulting from 
invasion of a mediastinal vessel; left vocal cord paralysis resulting from recurrent 
laryngeal nerve involvement by tumor or lymph node metastasis; malignant 
pleural effusion; and diaphragmatic paralysis. Jaundice and bone pain are 
systemic manifestations of organ metastases (10).
2.4.2.2 SCREENING AND DIAGNOSIS
Screening tests check for a disease in its early stages, before the symptoms 
develop. In case a person has Barrett's esophagus or tylosis, there is a high risk of 
esophageal cancer and should be regularly examined with endoscopy and 
biopsies. The best diagnosis is based on findings from an endoscopic examination 
of the esophagus (10).
2.4.2.3 SCREENING TESTS. 
2.4.2.3.1 Esophagoscopy (upper endoscopy). 
During this procedure, the doctor examines the inside of the esophagus using an 
endoscope - a thin, lighted tube with a tiny camera on the end that sends images to 
a TV monitor. The endoscope allows the doctor to clearly see any masses in the 
esophageal wall as well as to take a tissue sample (biopsy) of any abnormalities. 
This test also allows the doctor to determine if the patient has Barrett's esophagus 
and whether there is any need for its treatment and screening at more frequent 
intervals in the future (11).
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2.4.2.3.2 Barium swallow (Esophagram).
A diagnostic test often given to people who have difficulty swallowing, a barium 
swallow uses a series of X-rays to examine the esophagus. During the test, the 
patient is made to drink a thick liquid (barium) that temporarily coats the lining of 
esophagus so that the lining shows up clearly on the X-rays. Although a barium 
swallow can help diagnose cancer, it may not show whether a tumour has spread 
beyond esophagus. Upper gastrointestinal (GI) barium contrast studies help the 
doctor to detect cancers but may fail to detect small tumours more easily seen 
through endoscopy (11).
          Esophageal cancer therefore, still remains a devastating disease because it is 
usually not detected until it has progressed to an advanced incurable stage. 
Modern imaging techniques, including barium esophagraphy, contrast-enhanced 
computed tomography (CT), magnetic resonance imaging (MRI), endoscopic 
ultrasonography (EUS), and positron-emission tomography (PET), are some of 
the powerful tools used in the detection, diagnosis, and staging of this 
malignancy. Positron emission tomography scanning may be particularly useful in 
detecting lymph node metastases and bone spread. Early detection remains the 
elusive but essential goal of research. Only surgical resection at a very early stage 
has been shown to improve survival rates in patients with this disease (10). 
2.4.3 RISK FACTORS
2.4.3.1 ENVIRONMENTAL FACTORS
The following is a list of risk factors for esophageal cancer:
2.4.3.1.1 Long history of alcohol usage. Long-term heavy drinking irritates the 
lining of the esophagus, leading to inflammation that eventually may cause 
malignant changes in the cells (Tuyns et al 1988; (II)).
2.4.3.1.2 Tobacco usage. Tobacco consumption increases the likelihood of 
developing esophageal squamous cell carcinoma (V).
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Various studies have shown association between consumption of alcohol, tobacco 
and betel to esophageal cancer development. A case control study involving 447 
ESCC patients and 1022 controls from Taiwan, has shown that the genotoxic 
effect of the ADH1B and ALDH2 (genes modulating an individual’s alcohol 
metabolizing capacity), on ESCC may be linked to drinking behaviour (Lee et al., 
2007).  A synergistic interaction between tobacco and alcohol consumption was 
observed for the risk of esophageal SCC in Central and Eastern Europe, 
highlighting the importance of both factors for esophageal cancers. Risk estimates 
for tobacco smoking were highest for lower esophageal SCC’s, while risk 
estimates for alcohol drinking were highest for upper esophageal SCC’s; though 
differences were not statistically significant (Hashibe et al., 2007).
Findings from a population based case control study in Jiangsu Province, China 
involving 355 ESCC cases, provide evidence that dietary habits, tobacco smoking 
and alcohol drinking contribute to the etiology of esophageal SCC while as green 
tea drinking showed protective effects (Wang et al., 2007).
2.4.3.1.3 Occupational exposure. Various studies establishing a link between an 
increased risk of cancer and a particular working environment were published 
between 1950-1975 (VI). People working with dry cleaning solvents appear to 
have an increased risk of esophageal cancer (VII). 
2.4.3.1.4 Esophageal injuries, such as accidental ingestion of lye (a corrosive 
alkaline substance, commonly, sodium hydroxide (NaOH) (Melih T et al., 2003), 
thermal injury from a prolonged habit of drinking hot beverages, such as maté in 
South America predisposes an individual to esophageal cancer (De Stefani et al., 
1990). Chronic mucosal injury, due to the factors mentioned above, is the cause of
malignancy in several cases of esophageal cancer (II). 
2.4.3.2 OTHER FACTORS
2.4.3.2.1 Obesity has been associated with esophageal carcinoma, where people 
with high BMI (Body Mass Index) have been shown to be at a greater risk of 
developing esophageal adenocarcinoma (Kamat P., 2009), since gastric acid 
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refluxes are common in obese people (Chow et al., 1998; Lagergren et al., 1999; 
1999b; 2000; Bu et al., 2006; Corley et al., 2008; Friedenberg et al., 2008; 
Béchade et al., 2009). 
2.4.3.2.2 Diet. The consumption of fruits and vegetables associates with reduced 
risk of esophageal cancer. Eating a diet low in fruits and vegetables appears to 
contribute to esophageal cancer. Especially implicated are diets lacking in 
carotenoids, vitamins A, C and some among vitamin B (II; 1). People with low 
levels of the mineral selenium appear to have a slightly higher risk of esophageal 
cancer than do people with normal blood-selenium levels (12).
2.4.3.2.3 Chronic acid reflux. Sometimes the lower esophageal sphincter 
relaxes abnormally or weakens, allowing caustic stomach acids to back up into 
esophagus (esophageal reflux disorder). The result is heartburn- a burning chest 
discomfort that in severe cases may mimic the symptoms of a heart attack. 
Occasional heartburn usually isn't serious, but chronic acid reflux can lead to 
Barrett's esophagus, a condition in which cells similar to stomach's glandular 
cells develop in the lower esophagus. These new cells are resistant to stomach 
acid, but they also have a high potential for malignancy. Gastroesophageal reflux 
disorder (GERD) is the cause of about one-third of esophageal cancers. 
Smoking, obesity and a high-sodium diet add to the increased risk of reflux (12).
2.4.3.2.4 Human Papilloma Virus Infection. The role of HPV infection in the 
development of ESCC was reported in early 1980’s (Syrjanen et al., 1982; 
Syrjanen 1982). To date different HPV detection methods including morphology, 
immunohistochemistry (IHC), dot blot hybridization (DBH), in situ 
hybridization (ISH), southern blot hybridization (SBH) and PCR (polymerase 
chain reaction)have been used to study the role of HPV in ESCC (Syrjanen 
2002). HPV DNA has been detected in the surrounding hyperplastic and 
dysplastic epithelia in 5 % of the 700 ESCC patients screened in a high incidence 
area of Linxian, China (Chang et al 2000). HPV detection rates in esophageal 
carcinoma are highly variable in different geographical areas of the world, being 
significantly higher in high risk areas than in low risk areas.
       CHAPTER 2                                               Review of literature 
               Department of Biotechnology                    University of Kashmir    Page 17
2.4.3.3 GENETIC FACTORS 
Apart from the family history, esophageal cancer may also be associated with 
certain rare medical conditions, for reasons that aren't clearly understood; 
2.4.3.3.1 Esophageal web-It is a congenital soft web like structure of lower 
portion of esophagus causing dysphagia (13). When other problems such as iron-
deficiency anaemia and abnormalities of the tongue, fingernails and spleen, occur 
in conjunction with esophageal webs, the condition is called Plummer-Vinson or 
Paterson-Kelly syndrome. People with this syndrome are at risk of developing 
esophageal cancer (12).
2.4.3.3.2 Esophageal achalasia. In this disorder, food collects at the bottom of 
the esophagus, both because the esophagus lacks normal peristalsis to move food 
along and because of inability of the lower esophageal sphincter muscles to relax.
For reasons that aren't clear, achalasia seems to increase the risk of esophageal 
cancer (12). 
2.4.3.3.3 Tylosis. Excess skin develops on the soles and palms of people with 
tylosis, a rare inherited disorder. Close to half the people with tylosis eventually 
develop esophageal cancer. A genetic defect appears to be responsible for both 
tylosis and the associated cancer (12).
2.4.3.4. GENETIC ALTERATION or genetic damages, of two types, are 
encountered frequently in cancer cells: dominant (with targets known as 
oncogenes) and recessive (with targets known as tumor suppressor genes).
2.4.3.4.1 Oncogenes are those genes whose function is activated in cancer. This 
can be achieved by a number of simple molecular mechanisms, including point 
mutations that constitutively activate an enzyme, deletions that remove negative 
regulatory regions from proteins, or increased expression resulting from promoter 
deregulation or from multiplication of the number of copies of the gene (a 
phenomenon called “amplification”) (Savelyeva  et al., 2001). The non-activated 
counterpart of an oncogene is called a “proto-oncogene”. 
A proto-oncogene is infact a normal gene in all respects, often with important 
functions in the control of the signaling of cell proliferation, differentiation, 
       CHAPTER 2                                               Review of literature 
               Department of Biotechnology                    University of Kashmir    Page 18
motility or survival. Activation of an oncogene is a dominant mechanism, since 
alteration of a single allele is sufficient to confer a gain of function for cancer 
onset or progression (II). 
Many common proto-oncogenes encode components of the molecular cascades 
that regulate the cellular response to mitogenic signals (Hunter, 1991). They 
include growth factor e.g., TGFA, growth factor receptors e.g., receptors for 
epidermal growth factor, EGF and its close homologue, ERBB2), receptor-
coupled signal transduction molecules (in particular, several small GTP-binding 
proteins located on the inner face of the cell membrane, such as members of the 
RAS family), kinases ( SRC, ABL, RAF1), regulatory subunits of cell cycle 
kinases (CCND1 and CCNA), phosphatases (CDC25B), anti-apoptotic molecules 
(BCL2) and transcription factors (MYC, MYB, FOS, JUN) (I). The most 
commonly activated genes in human cancers are ERBB2 (oncogenic activation 
due to amplification), RAS (missense mutations) and MYC (Activation of Myc is 
often due to amplification but is also commonly activated by chromosomal 
translocation in some forms of B-cell leukaemia). These three genes are an 
excellent illustration of the diversity of mechanism of their activation and of their 
consequences for cell growth and division  (I). In esophageal cancer, amplification 
of a number of proto-oncogenes like Cyclin D1, HST-1, HST-2, EGFR, MYC has 
been reported (Montesano et al., 1996). 
2.4.3.4.2 Tumor suppressor genes (TSGs) can be defined as genes whose 
inactivation or alteration during carcinogenesis results in the loss of a functional 
property essential for the maintenance of normal cell proliferation. 
Loss of function of a tumor suppressor gene, is typically recessive and can be 
gene inactivation mechanisms like mutation, methylation or loss of alleles (most 
often through the loss of entire chromosomal sections encompassing several 
dozen genes), small deletions or insertions that scramble the reading frame of the 
gene, transcriptional silencing by alteration of the promoter region, or point 
mutations that change the nature of the residues that are crucial for the activity of 
the corresponding protein (II).
The combined effect of activation of oncogenes and inactivation of tumor 
suppressor genes drives the progression of cancer. The most evident biological 
consequences of these alterations are autonomous cell proliferation, increased 
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ability to acquire genetic alterations due to deregulated DNA repair, decreased 
apoptosis, capacity to invade tissues, and ability to activate the formation of new 
blood vessels (angiogenesis). None alone is sufficient in itself, but cancer arises 
when these five biological phenomena interact together into a chain of coordinated 
events that profoundly modifies the normal cellular pattern of growth and 
development (II)
Some of the main tumor suppressor genes studied extensively, due to their 
involvement in various carcinomas include p53, p16, Rb, BRCA1, BRCA2. The 
p53 gene is often found to be mutated and/or deleted in many forms of cancer 
(Baker et al., 1989), while as its inherited loss of p53 is shown to be associated 
with Li-Fraumeni syndrome, a rare familial syndrome of multiple cancers (Birch 
1994). BRCA1 and BRCA2 have been identified as involved in familial breast 
cancer risk (Zheng et al., 2000). Similarly p16INK4A has been found to be 
altered, in a variety of human cancers, by mechanisms like loss of alleles, 
mutations, hypermethylation and deletions (Gonzalez-Zulueta et al., 1995;1995b; 
Sherr, 2000; (II)).
2.5 TUMOUR SUPPRESSOR p16INK4A
P16 is a candidate tumor suppressor gene also known as CDKN2A (cyclin 
dependent kinase inhibitor 2), INK4A (inhibitor of kinase 4A), MTS1 (multiple 
tumor suppressor 1). It has been mapped on chromosome 9p21 (Serrano et al., 
1993). It contains 3 exons and encodes a 156 amino acid protein, previously 
identified as a cyclin dependent kinase inhibitor (CDKN2A) (Serrano et al., 1993; 
Lukas et al., 1995). It is an important component of cell cycle regulatory system 
and accomplishes its regulatory role by binding to and inhibiting the function of 
cyclin dependant kinases (Cdk4 and Cdk6), and to bring about cell cycle arrest at 
G1 (Serrano et al., 1993; Kamb et al., 1994; Shapiro et al.,  1998; Shapiro et al., 
2000).  The kinases Cdk4 and Cdk6 are known to phosphorylate the 
retinoblastoma (Rb) tumour suppressor protein, helping to cancel its growth-
inhibitory effects and enabling E2F transcription factors to activate genes required 
for entry into the DNA synthetic phase (S phase) of the cell division cycle (Sherr, 
2000). Therefore the outcome of functional loss of p16INK4a, is the loss of cell 
cycle control at G1/S checkpoint by the disruption of “the Rb pathway”.
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Fig.2.3 Outlining how p16INK4a regulates cell cycle through Rb pathway.
Loss of P16 function, rendering the protein unable to inhibit CDKs, can result in 
uncontrolled cell proliferation leading to tumorogenesis. p16INK4a gene deletions 
and other loss of function mutations, reported in a variety of tumors, substantiate 
its role as a tumor suppressor protein (Holland et al., 1994; Cairns et al., 1994; 
Caldas et al., 1994; Kamb et al., 1994b; Mori et al., 1994; Nobori et al., 1994; 
Hussussian et al., 1994; Lukas et al., 1995; Koh et al., 1995; Ranade et al., 1995). 
Frequent loss of heterozygosity (LOH) and/or homozygous deletion affecting 
chromosome 9p21-22 have been reported in a variety of primary tumors and cell 
lines (Holland et al 1994; Cairns et al, 1994). Chromosome 9, therefore, is 
presumed to contain a tumor suppressor gene(s) involved in the genesis of wide 
spectrum of human tumors. This gene has been proposed to constitute a potential 
target of point mutations and deletions in primary human tumors (Pollock et al., 
1996). The involvement of p16INK4a in the development of human tumors was 
implied by the observation that the INK4a locus (also called MTS1, CDK4I, or 
CDKN2) is mutated in many tumor-derived cell lines and maps to a chromosomal 
region frequently altered in human malignancies (Kamb et al., 1994; Nobori et al., 
1994; Okawhich et al., 1994).
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p16INK4a expression is known to be inhibited in a large number of cancers and 
reported to be mutated in a variety of human primary tumors and human cancer 
cell lines. The various alterations reported were in the form of deletion, mutation 
(Kamb et al., 1994; Lang et al., 1998), Hashemi et al, 2000; Faderl et al, 2000; 
Cachia et al, 2000; Mochizuki et al, 1999; Wang et al, 1999; Orlow et al, 1999; 
Kumar et al, 1999), rearrangement, insertion (Srivenugopal et al., 1996; 
Nakamura et al., 1999; Orlow et al., 1999; Garcia-Sanz et al., 1997), translocation 
(Duro et al., 1996; Borg et al., 2000; Monzon et al., 1998) and hypermethylation 
of CpG islands presented in promoter sequence (Goussia et al., 2000; Foster et al., 
1998; Kempster et al., 2000 Zhang et al., 1999; Wong et al., 1997; Park et al., 
2000; Salem et al., 2000). Such gene alterations consequently cause the in the 
change gene activity and hence structural change in p16 protein and loss of its 
physiological functions. In particular, point mutations and small deletions are 
common in pancreatic adenocarcinomas, esophageal carcinomas, biliary tract 
cancers, and in families with hereditary susceptibility to melanoma and pancreatic 
cancer (reviewed by Pollock et al., 1996; and by Hirama and Koefjectfler, 1995; 
see also Yoshida et al., 1995;Hussussian et al., 1994).
Furthermore it has also been reported that exoteric p16 gene when transfected into 
the cancer cells lacking p16 gene, the cell restored p16 gene expression and cell 
growth was remarkably inhibited. When cancer cell line with methylated CpG 
island of p16 gene was treated with 5-aza-2’-deoxycytidin, a methylation 
inhibitor, the cancer cell line restored p16 gene expression and showed growth 
inhibition. All these studies indicate that p16 gene and its product play an 
important role in carcinogenesis. 
This concept is also supported by the data showing that transfection of p16INK4a
causes G1 arrest in the human osteosarcoma cell lines U2OS (Medema et al., 
1995). Furthermore, co-transfection of p16INK4A with the oncogens c-myc and 
Ha-ras into rat embryo fibroblasts suppresses transformation by these oncogenes, 
thus demonstrating that p16INK4a indeed behaves like a tumour suppressor gene 
(Serrano et al., 1995). In both studies, co-transfection of CDK4 relieved the 
growth inhibitory effect of p16 INK4A indicating that CDK4 is a major target of this 
inhibitor.
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The locus encoding p16INK4a, named INK4a, has the capacity to give rise to two 
distinct transcripts from different promoters (Duro et al., 1995) Each transcript has 
a specific 5’exon, E1a or E1b, which is spliced into common exons E2 and E3. 
The E1a-containing transcript encodes p16INK4a, and the E1b-containing transcript 
encodes p19ARF (P14ARF in humans) from a different reading frame initiated in 
the E1b exon (Quelle et al., 1995a). p19ARF has the ability to arrest cell 
proliferation at both G1 and G2, albeit through mechanisms not involving direct 
inhibition of known CDK–cyclin complexes. Another level of complexity at the 
INK4a locus results from its close physical proximity to the gene encoding 
p15INK4b, an inhibitor thought to play an integral role in transforming growth 
factor (TGF)b–induced cell-cycle arrest. In general, the mutations in the INK4a 
locus that have been identified to date affect p16INK4a either exclusively or 
together with p19ARF.
P14ARF protein controls Mdm2, which in turn regulates p53 protein stability. 
Activation of P14ARF blocks Mdm2 and therefore results in p53 protein 
accumulation and activation.p53 in turn activates p21 which binds and inactivates 
certain CDK-Cyclin complexes which would otherwise carry the cell through the 
G1-S checkpoint of the cell cycle. Thus CDKN2A locus behaves as two unrelated 
but interlocked genes. The first gene encoding p16, directly controls cell cycle 
progression and senescence. The second, encoding p14ARF, controls p53 and all its 
downstream anti proliferative functions (II). 
Like other carcinomas, cancers of the upper gastrointestinal tract are characterized 
by a deregulation of the normal cell cycle with alteration of the G1/S checkpoint 
(Rb pathway)(Lin et al., 2004). 
Esophageal squamous cell carcinoma registers a variable spectrum of p16INK4a
mutations in different populations and these variations have been attributed to the 
influence exhibited by unique geographical and environmental factors a 
population is exposed to (Muzeau et al 1997). 
Esophageal cancer is the eighth most common cancer worldwide, responsible for 
462,000 new cases in 2002 (4.2% of the total), and sixth most common cause of 
death from cancer with 386,000 deaths (5.7% of the total). Cancer of the 
esophagus has a very poor survival: 14% of the cases in the United States (10) and 
10% in Europe (9) survive at least five years (Parkin et al 2005).
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Geographic variation in the incidence of esophageal cancer is very striking. Even 
at the level of world area, a 20-fold variation is observed between high-risk China 
and low-risk western Africa (Parkin et al 2005). Worldwide, certain geographic 
regions have a high incidence of esophageal squamous cell carcinoma. In 
particular, a belt of high incidence extends from the region of the Caspian Sea 
eastward through Central Asia to northern China. This is known as “Esophageal 
Cancer Belt”. Kashmir valley borders this belt on the southern side and the 
epidemiology of esophageal cancer has many peculiarities common to this belt. 
(Khuroo et al., 1992). The differences between incidences of esophageal cancer in 
distinct geographical areas are more extreme than observed for any other cancer 
(Landis et al., 1999; Pickens et al., 2003).
The valley has been reported as high-incidence area of esophageal squamous cell 
carcinoma (Matoo et al., 1974; Khuroo et al., 1992). ESCC accounts for 42.9% of 
all types of cancers in this region (Dhar et al., 1993). Kashmiri population 
represents a homogenous population which distinguishes itself with, unique 
geographical locale, intra community marriages, traditional dietary habits and 
unique cooking recipes. This high incidence has been associated with potential 
exposure to nitroso-compounds, amines and nitrates present in the local food 
stuffs, such as dried and smoked fish, red meat, dried pickled vegetables and 
traditional hot salted green tea (Nun Chai) (Siddiqi et al., 1988; 1989; 1991; 1992; 
Kumar et al., 1990).
In regions of the world with high incidences of esophageal and gastric cancer, 
extensive studies have failed to identify specific etiological factors. These studies 
have, however, strengthened the view that food habits and lifestyle are closely 
associated with a high incidence of esophagogastric cancer. (Kmet et al., 1972; 
Yang et al., 1980; Warwick et al., 1973; Siddiqi et al 1989; Malhotra et al., 1967).
Tumor suppressor p161NK4a is a typical example that shows variation both in the 
profile and frequency of mutations reported for ESCC subjects, the world over. 
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MATERIALS AND METHODS
3.1 Materials
Chemicals
3.1.1 Chemicals*
Acetic acid
Acrylamide
Agarose 
Amonium persulfate (APS) 
Ampicillin 
Bisacrylamide
Bromophenol blue
Calcium chloride
Coomassie brillant blue 
Ethanol
Ethidium bromide 
Ethylene diamine tetra acetate (EDTA)
Glycerol
Isopropyl-β-d-1-thiogalactoside (IPTG) 
LB Agar
LB Broth
N, N,N,N -tetramethylethylenediamine (TEMED) 
sodium dodecyl sulfate(SDS)
Tris base
x-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) 
*All the chemicals were of standard molecular biology grade.
3.1.2 Bacterial strains 
E. coli BL21(DE3) Novagen, Darmstadt 
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31.3 Vectors
pGEX-4T2 G .E, lifesciences, U.S.A
3.1.4 Enzymes for Cloning
E.corI Fermentas,Germany
XhoI Fermentas, Germany
T4 Ligase New England Biolabs.U.K
INSTA clone™ PCR Cloning Kit             Fermentas,Germany
3.1.5 Miscellaneous Materials
Protein Molecular Weight Marker Biogene,USA
100 bp DNA Ladder Fermentas, Germany
dNTP mix Fermentas, Germany
3.1.6 Reagents
3.1.6.1 Reagents for plasmid isolation
           Stratagene plasmid Miniprep kit
3.1.6.2 Reagents for DNA Amplification
dNTP mix                                                         Sigma
Primers (Forward and Reverse)                     Sigma
Taq polymerase                                                Sigma
Taq Buffer (Tris-HCl, KCl, (NH4)2SO4, 1.5mM MgCl2) (pH 8.7)
3.1.6.3 Reagents for gel purification of DNA
            Qiagen gel purification kit
3.1.6.4 Reagents for Cloning:
Luria-Bertani broth (2.5 g/100ml).
Luria-Bertani agar (3g/100ml).
Ampicillin (Stock 100mg/ml)
X-gal (5-bromo-4-chloro-3-indolyl- β-D-galactopyranoside)
IPTG (Isopropyl β-D-1-thiogalactopyranoside) 100mM
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3.1.6.5 Reagents for Site Directed Mutagenesis
            
          PhusionTm site directed mutagenesis kit          Finnizymes OY
         dNTP mix
         Primers(Sense and Antisense)
         PFU TURBO Polymerase
         HF Buffer
3.2 METHODS
3.2.1 PCR amplification of the p16INK4a cDNA
1. Indicated volumes of the following components were added sequentially to a 
0.2ml eppendorf tube on ice
S.no Reagent Volume(µl) Final 
conc.
1. MQ water 36.6 -
2. PCR buffer (10X) 5 1X
3. dNTP´s (2mM) 5 0.2mM
4. Sense 
primer(20pm/μl)
1.5 0.6 
pm/μl
5. Antisense 
primer(20pm/μl)
1.5 0.6 
pm/μl
6. Template DNA 0.2 60ng
7. Taq DNA 
polymerase(5U/μl)
0.2 0.2U/μl
Total volume 50
Table: 3.1
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2. Reaction was maintained on ice to undermine 3´-5´ exonuclease activity of the 
Taq polymerase which may otherwise cause degeneration of the primers.
3. Following program was used for   PCR
   Initial denaturation          -                5 minutes at 95ºC
Denaturation                    -                1 minute at 95 ºC
Primer annealing              -                1 minute at 60 ºC
Primer extension              -                1 minute at 72 ºC
Final extension                 -              20 minutes at 72 ºC
No. of cycles                    -                 30
4. After the amplification, 5µl of the sample was mixed with 1µl of 6X loading 
dye and the sample was electrophoresed on 2% agarose gel, and its size was 
determined by comparison to the mobility of 100 Bp DNA ladder.
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3.2.2 Agarose gel electrophoresis
The agarose gel electrophoresis was performed by standard procedure; the edges
of the tray were sealed with tape to form a mould. The tray was set on a leveled 
bench and an appropriate comb for forming the slot was positioned 0.5-1.0 mm 
above the plate to form the well when agarose is poured into the mould.
To 1.0 g agarose, 50ml of 1X TAE buffer was added in a flask, the slurry was 
heated on a hot plate till it formed a clear solution, then it was cooled to about 
50 ºC when Ethidium bromide was added to a final concentration of 0.5µg/ml. the 
gel solution was mixed thoroughly by gentle swirling. The agarose was poured 
into the casting tray and allowed to cool at room temperature till the gel solidified.
Then the comb was removed and it was put into the tank and covered with 1X 
TAE running buffer, and the sample was applied in one well and the DNA marker 
in other and they were run on 50 mA current and 100 V voltage till the molecular 
weight marker resolved fully. Then the gel was examined on a UV illuminator and 
photographed on a gel documentation system.
3.3.3 Gel purification of the amplified product
On confirmation of amplification, whole of the PCR amplified product was run on 
1.5% Agarose gel, the desired fragment was gel cut and DNA was purified by 
Qiagen gel purification kit according to manufacturer’s protocol.
3.3.4 Restriction digestion of the p16INK4a
Digestion of the amplified fragment was done with EcorI and XhoI as per the 
following protocol:
S.no Reagent Volume (µl) Final 
conc.
1. MQ water 12 -
2. Amplified product 16    100-200ng
3. 10X Tango buffer 10 2X
5. EcorI    1 (5000U/ ml) 0.16
XhoI    1 (5000U/ ml) 0.16
Total volume 50
              Table: 3.2
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Reaction was incubated at 37ºC for 16 hrs (overnight).
Digested product was purified by Qiagen DNA purification kit according to 
manufacturer’s protocol.
3.5.5 Restriction digestion of the pGEX-4T2
S.no Reagent Volume (µl) Final 
conc.
1. Plasmid DNA 6 10-100ng
2. 10X Tango buffer 2 2X
3. EcorI
1 (5000U/ ml)
0.5
4. XhoI 1(5000U/ ml) 0.5
Total volume 10
                Table: 3.3
Reaction was incubated at 37ºC for 1 hr.
Digested product was purified by Qiagen DNA purification kit according to 
manufacturer’s protocols
3.3.6 Ligation Reaction
The ligation reaction was carried out as per the following protocol:
S.NO Reagents Ligation 
mixture(µl)
Control 
reaction
(µl)
1. Vector DNA 3 3
2. Insert DNA 10 0
3. 10X ligase buffer 0.2 0.2
4. T4 DNA ligase 3 3
5. MQ water 13.8 20.8
Total volume 30 30
Table: 3.4
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The contents were vortexed and spun down for 3-5 seconds and incubated 
overnight at room temperature.
3.3.7 Preparation of competent cells
For the preparation of competent cells, 3ml LB broth was inoculated with BL21-
DE3 strain of E.coli and was grown overnight on a rotatory shaker at 37ºC at 230 
cycles/sec. After overnight growth 500 µl culture was transferred to 50ml LB 
broth taken in 500ml flask and was incubated for 3-4 hrs at 37ºC at 230cycles/sec 
until the O.D reached 0.5-0.6.Cell culture was cooled to 0ºC by keeping on ice for
10 minutes and the cells were harvested at 4000rpm for 10 minutes at 4ºC in a 
50ml polypropylene tube. Supernatant was discarded and the tubes were placed in 
inverted position to allow the last traced of medium to drain away. Pellet was 
resuspended by gentle vortexing in 10 ml of 0.1M ice cold calcium chloride and 
again stored on ice for 10 minutes. Resuspended cells were recovered by 
centrifugation at 4000 rpm for 10 minutes at 4ºC, supernatant was discarded and 
the pellet was resuspended by gentle vortexing in 2 ml of ice-cold calcium 
chloride. 300µl of glycerol was added to 2 ml of suspension and the suspension 
was mixed gently by swirling. Cell suspension was stored on ice till dispensed into 
50μl aliquots in chilled sterile 1.5ml storage tubes and stored at -80ºC until 
needed.
3.3.8 Transformation
Competent cells were thawed and stored on ice for 10 minutes, 5µl of ligation 
mixture was added to 50µl of competent cells in a micro centrifuge tube from both 
(vector + insert and the vector only) the ligations except the one that served as 
transformation control for ampicillin resistance. Cells were stored on ice for 30 
minutes. Transformation reaction was carried out by incubating the above mixture 
in a 42ºCwater bath for 45 seconds. After the heat pulse, cells were incubated on 
ice for 5 minutes followed by spreading on LB agar plate containing ampicillin at 
a concentration of 100µg/ml and the plates were incubated overnight at 37ºC.
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3.3.10 Plasmid isolation
Plasmid isolation was done using Stratagene plasmid Miniprep kit according to 
the manufacturer’s protocol.
3.3.11 Restriction digestion of the plasmid with same restriction enzymes 
used previously for cloning the insert
Restriction digestion of the recombinant vector was done to check the ligation of 
the insert in the vector 
S.no Reagent Volume(µl) Final 
conc.
1. Nuclease free 
water
6
2. Vector DNA 30 10-100ng
3. 10X Tango 
buffer
10 2X
4. EcorI 2 0.2U/ µl
5. XhoI 2 0.2U/ µl
Total volume 50
             Table: 3.6
Reaction was carried out in a 0.5 ml microfuge and the contents were mixed and 
spun down and incubated at 37ºC for 2 hrs.
3.3.12 CLONING AND CONSTRUCTION OF PGEX- P16INK4a ΔM(∆N307-∆N313)
Primers were used back to back on the vector backbone complementary to cDNA 
sequence of P16INK4a carrying the desired 7 Bp deletion using PhusionTm 
(Finnizymes OY.) site directed mutagenesis kit
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     Pipetting instructions for the site directed mutagenesis
S.no Reagent Volume(µl) Final 
conc.
1. MQ water UPTO 50 -
2. 5XHF buffer 10 1X
3. dNTP´s (10mM) 1 0.2mM
4. Sense primer(10pm/µl) 1 0.6 pm/μl
5. Antisense 
primer(10pm/µl)
1 0.6 pm/μl
6. Template DNA 0.2 20ng
7. PFU TURBO DNA 
polymerase(5U/ µl)
0.2 0.2U/ µl
Total volume 50
PCR program for site directed Mutagenesis
Following program was used for   PCR
            Initial denaturation          -                30 Seconds at 98ºC
Denaturation                    -               10 Seconds at 98 ºC
Primer annealing              -                1 minute at 58 ºC
Primer extension              -               5 minute at 72 ºC
Final extension                 -              10 minutes at 72 ºC
No. of cycles                    -                 25
Induction of the recombinant protein using IPTG
Single colony of transformed cells was inoculated in 5ml LB broth containing 
100μg/ml ampicillin and was allowed to grow overnight at 37ºC in a rotatory 
shaker with 230cycles/minute .After the overnight incubation, 200μl of culture 
was pipetted into 5ml LB broth containing 100µg/ml ampicillin and was 
incubated at 37ºC until OD reached 0.5-0.6. 1 ml culture was pipetted into a clean 
micro centrifuge tube and stored at 4ºC until needed for gel analysis. This served 
as non-induced control sample. To the rest of culture was added IPTG to a final 
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concentration of 0.1mM and was incubated for 3-4 hrs at 37ºC with shaking at 
220-230 rpm. After the induction period, cells were harvested at 12,000g for 1 
minute at room temperature. Cell pellet was then resuspended in 100μl of 1XSDS 
gel loading buffer, heated at 100º for 3 minutes and centrifuged at 12000g for1 
minute at room temperature. Control samples were treated similarly. Both control 
and treated samples were analyzed by SDS-PAGE.
3.3.13 Sodium Dodecyl Sulphate Polyacrylamide gel electrophoresis (SDS-
PAGE) analysis of the recombinant protein.
SDS-PAGE was performed using the method of lamelli et al. Samples were 
electrophoresed on a slab gel (0.75mmthick) that consisted of 5% stacker and 12% 
resolving gel. On an average 1.5 cm long stacking and 4cm long separating gel 
was used and routine electrophoretic run was performed at 100Vuntill the proteins 
entered the resolving gel and at 70V constant thereafter .
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        Results & Discussion
p16INK4a also known as CDKN2A, INK4A or MTS1, is an important component of 
cell cycle regulatory system.  It forms binary complexes with the cyclin dependent
kinases CDK4 and CDK6, inhibiting their ability to phosphorylate the RB protein 
(Serrano, M., 1993). Un-phosphorylated RB prevents the cell from entering the cell 
cycle. Loss of p16 function, rendering the protein unable to bind & inhibit CDKs, can 
result in uncontrolled cell proliferation leading to tumorogenesis. p161NK4a gene 
deletions and other loss of function mutations, reported in a variety of tumors,  
substantiate its role as a tumor suppressor 
      Our lab has recently identified a novel 7 Bp deletion  in exon 2 of p161NK4a gene 
in a group of ESCC patients from Kashmir valley (Figure.1 & Figure.2).Several 
mutations in p161NK4agene in other populations have been found to reduce its binding 
affinity with CDK. Studies have also revealed that inhibition is associated with 
p161NK4a binding to CDK4. p161NK4a is an ankyrin repeat protein, containing four 
ankyrin repeats (I-IV), each having a helix-turn-helix structure. . Ankyrin repeat 
domain in p161NK4a has come to be the focus due to the studies wherein it was 
established that the integrity of this region is important, both for structural as well as 
functional properties of p161NK4a protein. The mutation, we have identified 
incidentally falls in this conserved part of the protein and could thus be highly 
significant with regard to function of p161NK4a. A 7 bp deletion observed by us in 
Kashmiri population causes a frame shift in p161NK4a leading to deletion of a major 
portion of the carboxy terminus of p161NK4a.This mutation has the potential to 
seriously hamper the functioning of the protein. We have therefore chosen to 
investigate the effect of this mutation on the interactive and regulatory role of 
p161NK4a in cell cycle. (Qureshi et al)
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Figure 4.1 CSGE gel picture showing the heteroduplex formation in the mutant Alleles
( Reproduced with permission from Qureshi, M ( 2007)
Following work plan was devised to generate the WT and Mutant allele compatible       
for Bacterial Expression:
Obtaining p161NK4a cDNA.
 Synthesis of primers flanking cDNA of p161NK4a gene, with overhangs compatible 
with the vector to be used.
Amplification of p161NK4a cDNA
Cloning of wild type allele in the compatible expression vector (pGEX-4T2).
Generation of p161NK4a mutant harboring 7bp deletion mutation using PCR based 
site directed mutagenesis program.
Expression of GST-fusion protein (Wild type and Mutant) in bacterial host.
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A cDNA encoding human p161NK4a cloned in pCMV was commercially obtained
(Addgene Inc.).                
                                   Figure 4.2 Vector map of pCMV p16INK4a
                                             
                          Figure 4.3 Gel picture of pCMV-p161NK4a
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Oligonucleotides flanking p161NK4a cDNA were designed with forward primer 
carrying EcoRI site & the reverse primer carrying XhoI site.
Forward Primer:
CGCGAATTCTTATGGAGCCTCGGCTGACTGGC
Reverse Primer:
CGCATGCTCGAGTCAATCGCGGATATCGAG
GAATTC---------EcorI site
GAGCTC---------XhoI site
Using the above shown primers, PCR was performed with p161NK4a cDNA as 
template and the amplified product was obtained.
        
Figure 4.4 Agarose gel picture showing amplification of 472bp fragment representing the coding 
sequence of p161NK4a. Lane 1 represents 100bp ladder, lane 2 represents negative control, lane 3-
5 represents the amplified product.   
    
pGEX-4T2 (expression vector) and the insert (p161NK4a)   were digested separately 
with EcorI and XhoI. The insert and the vector after purification were ligated using 
T4 DNA ligase.
PCR Amplified product
CHAPTER 4                               
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The construct was then transformed into an appropriate E.coli host BL21
production of the recombinant protein.
made competent & transformed with
LB-agar containing ampicillin which served as the selection marker. About 50
transformants were obtained.
                               Results & Discussion  
                                                 University of Kashmir
Figure 4.5 Vector map of pGEX-4T2
Using calcium chloride method
p161NK4a cDNA. The cells were then plated on 
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-DE3 for 
, the cells were 
-100 
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Figure 4.6 Transformation and selection of pGEX4T2-p16INK4a.Ligation reaction aliquot having
pGEX4T2 (~5-10ng) and p16INK4a amplicon (15-30ng), was transformed in about 20µl aliquot of 
competent bacteria (BL21DE3).Bacterial colonies represent the ones bearing the recombinant 
plasmid.
A mini prep isolation of plasmid DNA was generated and Agarose gel electrophoresis 
confirmed the presence of plasmid which was subsequently digested with the same restriction 
enzymes (as used for cloning) to confirm the presence of insert.
                                                 
Figure 4.7 Restriction digestion of recombinant pGEX-4T2: Recombinant plasmid was isolated 
as a miniprep from ampicillin resistant colony inoculum and subjected to restriction digestion 
using EcoRI and XhoI restriction enzymes and the digests were analysed on 1% agarose gel.
Lane 1 represents undigested vector (1µg), lane 2 represents EcoRI digested vector (linearized 
vector) (1 µg),lane 3 represents double digested vector showing the appropriate sized insert, lane 
4 represents 1Kb ladder.
Insert 
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                  Site Directed mutagenesis of p16INK4a Wild Type
                     Figure 4.8 Flowchart depicting the procedure for site-directed mutagenesis
                           
Primers used for mutagenesis to construct mutant p16INK4a
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                       Forward primer
                                  5-----Phos ACGTGCGCGATGCCTGGGGCCGTCT---3
                       Reverse Primer
                                       5----Phos CGCCCCGGCCCGGTGCAGCACCAC---3
A 5.2 Kb band on agarose gel confirmed the success of PCR which was then ligated with T4 
DNA ligase using standard protocol and transformed in E.Coli Bl21-De3
                         
  Figure 4.9 Agarose gel picture showing amplification of 5.2kb product representing p16INK4a    
with incorporated 7bp mutation. Lane1 represents 100bp DNA ladder, Lane 2,3 shows PCR 
amplified mutagenized pCMV-  . Lane 4 represents control vector (pCMV- p16INK4aWT)
p161NK4a WT and Mutant cDNA were expressed in BL21-DE3 as GST fusion protein 
and was induced with IPTG for the production of recombinant protein, which was 
analyzed by SDS-PAGE showing the production of 43 and 42 kDa proteins 
respectively, in conformity with the calculated size of the recombinant proteins.
Mutagenesis 
template 
PCR product
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Figure 4.10 12% SDS-PAGE Gel showing induction of GST.p16WT (GST fusion) &p16ΔM
(∆N307-∆N313) (GST-fusion) protein. Lane.1: represents molecular weight marker (10-250KDa)   
Lane.2,3 shows uninduced & induced GST respectively. Lane.4, 5 shows un-induced & Induced 
GST- p16INK4a. Lane 6, 7 represents induced and uninduced GST-p16Δm.Each lane represents 
150µg of the total protein.
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